Eli Lilly and Company, a global pharmaceutical giant based in Indianapolis, IN, has acquired Morphic Holding, Inc., a biopharmaceutical company focused on developing oral integrin therapies for chronic diseases.

Expanding Treatment Options for Chronic Diseases

The acquisition aims to bolster Lilly’s capabilities in treating inflammatory bowel disease (IBD) by incorporating Morphic’s innovative therapies into its portfolio. Morphic is known for its development of MORF-057, a selective oral small molecule inhibitor of α4β7 integrin, specifically designed for the treatment of IBD.

Strategic Acquisition for Enhanced Patient Outcomes

While the financial details of the transaction were not disclosed, this strategic acquisition is expected to improve treatment outcomes and provide more options for patients suffering from serious chronic conditions like IBD. Lilly’s acquisition of Morphic underscores its commitment to expanding its therapeutic offerings and addressing unmet medical needs in the field of chronic disease management.